The timing and co-ordination of the cell cycle progression is governed by the cyclin-dependent protein kinases (CDKs). Inhibitors of these enzymes block the progression of the cell cycle and are of interest as antiproliferative agents in anticancer drug research. The potent low-molecular weight inhibitors prevent binding of the co-factor ATP to the enzyme [1-3]. At Schering we have evaluated three diverse lead series of CDK2-inhibitory compounds: aminopyrazoles, aminopyrimidines and indirubines. Although a large number of crystal structures of CDK2 in complex with a variety of ligands are known, the correct binding mode of new inhibitors is often difficult to predict. This fact is mostly based on the relatively high flexibility of the active site. Thereupon our aim was to identify the exact binding modes of our three lead series within the ATP-site and to further on optimize these leads by structure-based design. [4-6]. CDK2 features a typical kinase fold: The N- and C-terminal domains are linked by the hinge region. ATP or its competitors bind in the cleft between the two